Neuroleptic malignant syndrome in patients with COVID-19
We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Mitsuhito So, Toru Hifumi, Shutaro Isokawa, Masato Shimizu, Norio Otani, Shinichi Ishimatsu Source Type: research
More News: Brain | Cancer & Oncology | Coronavirus | COVID-19 | Diprivan | Emergency Medicine | Fentanyl | Intensive Care | Neurology | Propofol | Respiratory Medicine